Assembly Biosciences, Inc. (ASMB)

NASDAQ: ASMB · Real-Time Price · USD
21.22
+1.79 (9.21%)
Aug 7, 2025, 4:00 PM - Market closed
9.21%
Market Cap162.81M
Revenue (ttm)33.25M
Net Income (ttm)-38.96M
Shares Out 7.67M
EPS (ttm)-5.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume145,335
Open19.49
Previous Close19.43
Day's Range19.49 - 22.46
52-Week Range7.75 - 22.50
Beta0.65
AnalystsStrong Buy
Price Target33.00 (+55.51%)
Earnings DateAug 6, 2025

About THRX

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinica... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 17, 2010
Employees 73
Stock Exchange NASDAQ
Ticker Symbol ASMB
Full Company Profile

Financial Performance

In 2024, Assembly Biosciences's revenue was $28.52 million, an increase of 298.16% compared to the previous year's $7.16 million. Losses were -$40.18 million, -34.38% less than in 2023.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for ASMB stock is "Strong Buy." The 12-month stock price target is $33.0, which is an increase of 55.51% from the latest price.

Price Target
$33.0
(55.51% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

– On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, AB...

1 day ago - GlobeNewsWire

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elev...

1 day ago - GlobeNewsWire

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

12 days ago - GlobeNewsWire

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

– Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b...

5 weeks ago - GlobeNewsWire

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort –

6 weeks ago - GlobeNewsWire

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to...

2 months ago - GlobeNewsWire

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fal...

3 months ago - GlobeNewsWire

New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection mark...

3 months ago - GlobeNewsWire

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations –

4 months ago - GlobeNewsWire

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –

5 months ago - GlobeNewsWire

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will...

5 months ago - GlobeNewsWire

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose ...

6 months ago - GlobeNewsWire

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –

8 months ago - GlobeNewsWire

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented –

1 year ago - GlobeNewsWire

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –

1 year ago - GlobeNewsWire

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at t...

1 year ago - GlobeNewsWire

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to...

1 year ago - GlobeNewsWire

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, ...

1 year ago - GlobeNewsWire

Assembly Biosciences Announces Effective Date of Reverse Stock Split

– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 –

1 year ago - GlobeNewsWire

Assembly Biosciences Provides Anticipated Development Milestones for 2024

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral d...

1 year ago - GlobeNewsWire

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral d...

1 year ago - GlobeNewsWire

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRA...

1 year ago - GlobeNewsWire

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases.

Other symbols: GILD
1 year ago - Business Wire

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company's interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLOB...

1 year ago - GlobeNewsWire

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected –

2 years ago - GlobeNewsWire